1   **False-Negative Molecular Diagnosis of SARS-Cov-2 in Samples with Amplification Inhibitors**

3   Marcelo Fruehwirth[1], Açucena Veleh Rivas[1], Andressa Faria Rahyn Fitz[1], Aline Cristiane Cechinel

4   Assing Batista[1], Cleypson Vinicius Silveira[1], Robson Michael Delai[1]

6   [1] Centro de Medicina Tropical da Tríplice Fronteira, Fundação de Saúde Itaiguapy, Av. Araucária,

7   1734 - Vila A, 85866-010, Foz do Iguaçu, Paraná, Brazil

9   *Corresponding author: Marcelo Fruehwirth. Centro de Medicina Tropical da Tríplice Fronteira,

10   Fundação de Saúde Itaiguapy, Av. Araucária, 1734 - Vila A, 85866-010, Foz do Iguaçu, Paraná, Brazil

11   E-mail: marcelo.fruehwirth@hmcc.com.br / Phone: +55 (45) 3029-1733.

13   **Abstract**

14

15   Although rRT-PCR is the gold standard method for SARS-CoV-2 detection, some factors, such as

16   amplification inhibitors presence, lead to false-negative results. Here we describe differences between

17   rRT-PCR results for SARS-CoV-2 infection in normal and diluted samples, simulating the need for

18   dilution due to amplification inhibitors presence. Viral RNA extraction of nasopharyngeal swabs

19   samples from 20 patients previously detected as 'Negative' and 21 patients detected as 'Positive' for

20   SARS-CoV-2 was realized with the EasyExtract DNA-RNA (Interprise®) for extraction. rRT-PCR was

21   realized with OneStep/COVID-19 (IBMP) kit with normal and diluted (80µl of H_2O RNAse free)

22   samples, totaling 82 tests. The results indicate that there is an average variation ($\alpha < 0.05$) delaying Ct

23   between the amplification results of internal control (IC), N Gene (NG), and ORF-1ab (OF) of 1.811Ct,

24   3.840Ct, and 3.842Ct, respectively. The extraction kit does not completely purify the inhibitor

25   compounds, therefore non-amplification by inhibitors may occur. In this study, we obtained a 19.04%

26   false-negative diagnosis after sample dilution, and this process reduces the efficiency of rRT-PCR to

27   29.8% for detecting SARS-CoV-2. Knowing the rRT-PCR standards of diluted samples can help in the

28   identification of false-negative cases, and consequently avoid a wrong diagnosis.

29

30

31   **Keywords:** COVID-19; rRT-PCR; dilution; viral diagnosis; RNA extraction

32

33

34

1.   Introduction

The first confirmed case of Coronavirus disease 2019 (COVID-19) in Latin America occurred in Brazil, on February 25, 2020 [1]. Since then, until August 2020, Brazil has recorded about 4.1 million cases and about 126 thousand deaths due to COVID-19 [2].

Early detection of infected individuals with large-scale testing, immediate isolation of cases with tracking and preventive self-isolation of close contacts, and prompt treatment of severe cases are essential measures to reduce the spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [3].

Therefore, to quickly diagnose infections and mitigate transmission of SARS-CoV-2, the Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) is being used as the primary method in research and hospital laboratories to identify the virus in respiratory samples such as sputum or nasal, throat, nasopharyngeal swabs [4].

rRT-PCR tests typically take 4 to 6 hours to complete, with RNA extraction, amplification, and detection [5]. Considering the limited supply of extraction reagents and test kits worldwide, extraction kits without RNA purification aim to solve this limitation and short the extraction time, thereby shortening the response time [4,5].

However, amplification inhibitors, organic and inorganic substances, can be present in original samples or be introduced in samples transportation, processing, or RNA extraction, causing partial amplification inhibition, leading to a decrease of PCR sensitivity or total inhibition and consequently false-negative results [6].

Extraction kits without RNA purification may need to optimized the rRT-PCR by sample dilution when there are problems with rRT-PCR amplification, thus minimizing the presence of amplification inhibitors [7], allowing amplification even if there are inhibitors or some sample degradation, avoiding the need to request a new sample from the patient, however, it is necessary to know the diluted amplification patterns, avoiding false-negative diagnosis.

Due to the severity of the pandemic, test kits were and are being developed and approved quickly, to meet the worldwide demand for large-scale tests, creating the need for information on real data on the use of these kits in diagnostic laboratories [8]. Here we describe differences between rRT-PCR results for SARS-CoV-2 infection in normal and diluted samples, simulating the need for dilution due to amplification inhibitors presence.

66   **2.   Materials and Methods**

67

68   2.1.   *Nasopharyngeal swab samples of RNA extraction*

69

70   Nasopharyngeal swabs samples from 41 patients admitted to the Ministro Costa Cavalcanti

71   Hospital in Foz do Iguaçu, Paraná state - Brazil, were selected. Twenty of these patients were previously

72   detected as 'Negative' and 21 patients were detected as 'Positive' for SARS-CoV-2 infection in rRT-PCR

73   diagnosis. The swabs were stored in tubes with 1x Phosphate-Buffered Saline (PBS 1x), at -20ºC, until

74   extraction.

75   The EasyExtract DNA-RNA kit (Interprise®), lot ITBR0720, was validated by comparing the

76   results found using the Applied Biosystems™ MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit

77   results (Thermo Fisher Scientific®), lot 200312, at 1% significance level (N = 96). For the viral RNA

78   extraction, 20µl of reagent EasyExtract DNA-RNA (Interprise®), was mixed with 20µl of PBS 1x from

79   the swab samples in 1,5mL Eppendorf tubes. The tubes have been shaken in a vortex mixer (Kasvi, K45-

80   2810) at 1,050 rpm for 15 seconds, incubated at 95º C for 5 minutes, and refrigerated at -20º C for RNA

81   stabilization [7].

82

83   2.2.   *Samples dilution and rRT-PCR for SARS-CoV-2*

84

85   The samples were diluted in 80µL of UltraPure® H_2O RNAse free (1:2), totaling 82 tests (41

86   normal samples and 41 diluted samples).

87   The rRT-PCR assay was performed using the Biomol OneStep/COVID-19™ Kit (IBMP), lot

88   200399Z074, 15µL of the Reaction rRT-PCR Mix and 5µL of purified sample RNA (from RNA

89   extraction) or purified Negative Control, were mixed by pipetting up and down, and for positive control,

90   15µL of the Reaction Mix were mixed with 5µL of Positive Control [9].

91   The analysis was performed using the QuantStudio™ 5 Real-Time PCR Systems equipment

92   (Thermo Fisher Scientific®), under the conditions: Hold Stage: 50º C for 15 minutes (1 cycle), 95º for

93   3 minutes (1 cycle); PCR Stage: 95º C for 15 seconds e 55º C for 40 seconds (40 cycles) and Hold Stage:

94   25º C for 10 seconds (1 cycle). The threshold values of the Internal Control (ROX), ORF1ab (FAM),

95   and GENE N (HEX / VIC) were 20,000.0, 30,000.0, and 40,000.0 respectively, with a baseline from 5

96   to 15, according to the IBMP protocol [9].

97   The results were evaluated by the rRT-PCR amplification standards, amplification values, and
98 submitted to descriptive analysis, normality test and variance analysis (ANOVA), to detect differences
99 between the results found before and after dilution.

100

101 2.3.   *Efficiency of the rRT-PCR*

102

103   The analytical efficiencies for detecting SARS-CoV-2 from the normal methodology and after
104 dilution were performed by serial dilution in the following proportions: 1, 1:2, 1:4, 1:8, and 1:10. The
105 results were evaluated by scatter plots and the efficiency values calculated from the R^2 of the linear
106 regression.

107

108 **3.   Results**

109

110   The results are described in Table 1. Comparisons between diluted and undiluted sample results
111 indicate that there is an average variation ($\alpha < 0.05$) delaying Ct between the amplification results of the
112 internal control (IC), N Gene (NG), and ORF-1ab (OF) of 1.811Ct, 3.840Ct, and 3.842Ct, respectively.
113   The Ct means of the Internal Control were 29.423 for original samples and 31.280 for diluted
114 samples; for N Gene, the mean Ct of the original value was 25.816 and 29.848 for diluted samples; for
115 ORF-1ab, the average Ct results for samples without dilution were 27,104 against 31,138 for diluted
116 samples.

117

118 **Table 1.** Results of the rRT-PCR ΔCt amplification of normal and diluted samples. The variations were
119 calculated considering the values of the original samples as the true Ct.

Diagnose	Sample ID	IC	IC*	NG	NG*	OF	OF*	ΔIC	ΔNG	ΔOF
Negative	1	26,224	28,376	-	-	-	-	-2,152	-	-
	2	28,941	31,024	-	-	-	-	-2,083	-	-
	3	29,585	31,871	-	-	-	-	-2,286	-	-
	4	29,436	30,428	-	-	-	-	-0,992	-	-
	5	32,186	34,128	-	-	-	-	-1,942	-	-
	6	30,660	32,673	-	-	-	-	-2,013	-	-
	7	27,193	29,721	-	-	-	-	-2,528	-	-
	8	29,451	31,890	-	-	-	-	-2,439	-	-
	9	29,092	31,230	-	-	-	-	-2,138	-	-
	10	25,364	27,492	-	-	-	-	-2,128	-	-
	11	30,608	32,700	-	-	-	-	-2,092	-	-
	12	29,246	31,522	-	-	-	-	-2,276	-	-
	13	30,690	32,037	-	-	-	-	-1,347	-	-
	14	28,590	30,194	-	-	-	-	-1,604	-	-
	15	27,598	28,500	-	-	-	-	-0,902	-	-
	16	27,651	29,382	-	-	-	-	-1,731	-	-
	17	28,691	30,320	-	-	-	-	-1,629	-	-
	18	25,980	27,693	-	-	-	-	-1,713	-	-
	19	28,382	31,124	-	-	-	-	-2,742	-	-
	20	27,813	29,600	-	-	-	-	-1,787	-	-
Positive	21	28,941	30,974	21,011	24,046	19,121	21,320	-2,033	-3,035	-2,199
	22	27,536	29,633	19,276	22,270	24,767	27,180	-2,097	-2,994	-2,413
	23	29,052	31,038	22,909	24,030	27,013	29,706	-1,986	-1,121	-2,693
	24	29,668	31,944	17,969	23,490	25,689	28,211	-2,276	-5,521	-2,522
	25	**29,488**	**32,191**	**21,520**	**35,000**	**28,990**	**40,000**	**-2,703**	**-13,480**	**-11,010**
	26	**30,437**	**32,970**	**20,175**	**32,377**	**28,299**	**40,000**	**-2,533**	**-12,202**	**-11,701**
	27	28,067	29,983	23,868	28,955	24,136	26,759	-1,916	-5,087	-2,623

28	22,793	23,674	24,278	25,226	25,345	26,093	-0,881	-0,948	-0,748
29	23,423	25,454	21,491	24,937	21,280	25,490	-2,031	-3,446	-4,210
30	26,926	28,030	17,773	21,417	17,873	21,780	-1,104	-3,644	-3,907
31	30,772	30,907	31,018	31,312	29,833	31,767	-0,135	-0,294	-1,934
32	28,332	30,406	24,273	27,285	23,178	25,684	-2,074	-3,012	-2,506
33	27,453	28,774	28,912	30,416	27,939	29,197	-1,321	-1,504	-1,258
34	29,475	30,981	24,052	25,287	23,684	24,918	-1,506	-1,235	-1,234
35	32,237	32,427	27,702	31,440	27,225	30,644	-0,190	-3,738	-3,419
36	26,155	28,695	27,684	31,167	27,783	30,702	-2,540	-3,483	-2,919
37	29,219	31,453	27,088	30,406	26,308	29,036	-2,234	-3,318	-2,728
38	28,364	30,639	24,162	28,913	24,462	27,117	-2,275	-4,751	-2,655
39	**31,006**	**32,548**	**32,500**	**35,380**	**32,914**	**40,000**	**-1,542**	**-2,880**	**-7,086**
40	**31,776**	**32,410**	**34,074**	**35,756**	**32,333**	**40,000**	**-0,634**	**-1,682**	**-7,667**
41	32,434	34,160	24,577	27,840	23,906	27,165	-1,726	-3,263	-3,259

* = Samples diluted in 80μL; IC = Internal Control Ct; NG = N Gene Ct; OF = ORF-1ab Ct; Δ = Ct variation.

Before dilution, samples 25, 26, 39, and 40 showed lower values than the cut-off stipulated for ORF-1ab, being considered positive. After dilution, they all shifted the ORF-1ab Ct values to the right and are then considered negative due to non-amplification within the cut-off parameters (Figure 1).

137   **Figure 1**. Amplification of ORF-1ab from samples 25 (a), 26 (b), 39 (c) and 40 (d) before (.1) and after

138   (.2) dilution.

139

140

141   The normality test considered normal values for Internal Control and N Gene (α > 0.05),

142   however, for ORF-1ab the values were considered out of normal (α < 0.05) (Figure 2). When removing

143   outliers, the data returns to normal, indicating that the amplification values of samples 25, 26, 39, and

144   40 are not within the expected range, indicating a great variation with the other samples ($\alpha > 0.05$).

145

146   **Figure 2.** Scatter diagram of Internal Control, N Gene, and ORF-1ab from the normality test.

147

148

149   **Figure 3.** rRT-PCR efficiency scatter plot of normal sample (a) and dilution sample (b).

15

151

152

153

154

155

156

157 **4.**   **Discussion**

158

159   The positive control showed amplification for the 3 targets evaluated in all tests (Ct ≤ 35) and

160 the negative control did not show any amplification for the three evaluated targets, according to the mix

161 manufacturer's protocol, validating the results.

162   The tests performed to demonstrate 1:2 dilutions were interesting to obtain a reliable

163 amplification in samples with inhibitors, as shown in Figure 4. However, it is important to pay attention

164 to the result curve patterns after dilution.

165

166 **Figure 4.** Differences in amplification patterns of a sample with inhibitors before (a) and after (b)

167 dilution.

169   In the example shown in figure 4.a, the sample without dilution did not obtain amplification of

170 the internal control (Ct = undetermined value) and OF patterns (Ct = undetermined value), and NG (Ct=

171 29,995) not defined and not showing a perfect exponential curvature. After dilution (b), the perfect

172 amplification of the three markers is perceived, indicating a superior sample quality and the absence of

173 inhibitors. The Ct values of the amplifications were 29,951 for the IC, 25,444 for the NG, and 27,579

174 for OF.

175   In cases like in Figure 4, only dilution is sufficient to diagnose the sample as positive, avoiding

176 new patient stress when redoing the collection, and new exposure by the health professional, sending the

177 infected patient to the correct area for treatment in a short time, with a low period between collection

178 and diagnosis. However, in cases where the result after the dilution is negative, a series of precautions

179   should be taken when releasing the diagnosis, such as curve characteristics, evaluating the graph

180   completely and not just the values that exceeded the Ct.

181   According to the Thermo Fisher® manual, considering a process efficiency of 100%, there is a

182   known variation in Ct when the sample is diluted, being variable according to the proportion of the

183   dilution. This dilution variation can be $\Delta Ct = 1$ from 1:2, $\Delta Ct = 2$ from 1:4, $\Delta Ct = 3$ to 1:8 and $\Delta Ct = 3{,}3$

184   from 1:10. However, these values vary according to the efficiency of the process and presence of

185   inhibitors [10], which can result in false-negative diagnosis in low viral load samples, depending on the

186   value used as a parameter to distinguish between positive and negative.

187   Figure 3 shows the efficiency of the normal (a) and diluted (b) sample amplification process. The

188   amplification efficiency for the normal sample was 99.79% for CI, 99.51% for NG, and 97.09% for OF,

189   which indicates a high efficiency of the extraction process [10]. For the diluted sample, the amplification

190   efficiency was 98.88% for CI, 78.33% for NG, and 67.29% for OF, indicating a decrease of 21.18% for

191   NG detection and 29.8% for OF detection.

192   Positive samples tested that had divergent results after dilution obtained ΔCt values between 28

193   and 33, which should not make them negative after dilution even with low efficiency in the amplification

194   process, since there was a variation between 8 and 12 Ct (Figure 1). Considering the progression of ΔCt

195   according to greater dilutions, the dilution proposal by the manufacturer of the viral RNA extraction kit

196   (1:10) would not be interesting, as theoretically 1:10 would cause the Ct values to be even later. Larger

197   tests involving smaller dilutions can be performed, verifying in what proportion there would be no

198   significant differences in the Ct values and effectiveness in the dilution of rRT-PCR inhibitors.

199   The importance of performing rRT-PCR in kits that provide internal control marking has already

200   been reported by Kim et al., 2016, generating conclusive results about the extraction process, avoiding

201   the release of false-negative results in samples that were not amplified with precision since the

202   interpretation of results is not always straightforward. The sensitivity of the rRT-PCR is negatively

203   impacted by compounds present in the clinical sample that may partially or completely inhibit rRT-PCR

204   chemistries [11 - 15].

205   Protocols with purification steps can avoid the presence of amplification inhibitors, removing

206   potential endogenous rRT-PCR inhibitors such as detergents, chelating compounds, and guanidinium

207   HCl [11, 13, 16 - 19]. The efficiency of removing inhibitors in patient samples may be related to the

208   intrinsic properties of the method used to extract the RNA [20], what does not happen in the kit used in

209 this study. The Easy Extract™ kit does not completely purify the inhibitor compounds, which
210 significantly reduces the extraction time, however, non-amplification by inhibitors may occur.

211   A diagnostic error can lead infected patients to non-COVID-19 areas with the subsequent risk of
212 infection for others; or patients which are negative SARS-CoV-2 sent to COVID-19 areas [21],
213 generating possible contamination to uninfected patients and also the spread of viruses in the disinfected
214 areas, which can lead to viral spread within hospitals and treatment centers, and contaminate the health
215 workers. Knowing the rRT-PCR standards of diluted samples can help in the identification of false-
216 negative cases, and consequently avoid a wrong diagnosis.

217

218 **5.**   **Conclusion**

219

220   The 1:2 dilution of the sample with inhibitors in UltraPure® H_2O RNA*se free* generated
221 amplification in 100% of the tested cases, being an alternative to avoid new sample collection in the
222 patient. However, we emphasize that in this study we obtained 19.04% false-negative diagnosis after
223 sample dilution, and this process reduces the efficiency of rRT-PCR to 29.8% for detecting SARS-CoV-
224 2. It is possible to infer that the dilution helps in cases where a new sample collection is not feasible, but
225 caution is needed in the evaluation of the result of the rRT-PCR.

226   It is important to assess the pattern of the amplification curves after dilution to avoid inaccurate
227 diagnosis. If the sample with inhibitors is positive with a high viral load, the result will be reliable if
228 Internal Control and Gene N amplification occur up to Ct 30 and ORF-1ab up to Ct 35. In the case of
229 non-amplification of the N Gene and ORF-1ab curve after dilution, we recommend assessing the need
230 for a new sample and new analysis.

231

232 The authors declare no conflict of interest.

233

234

235 **Acknowledgments:**

236

237   To Itaipu Binacional, Itaiguapy foundation and Ministro Costa Cavalcanti Hospital for their
238 support.

239

References

[1] Rodriguez-Morales, A.J., et al. "COVID-19 in Latin America: The implications of the first confirmed case in Brazil." *Travel medicine and infectious disease* **2020**, *35*, 101613; DOI: 10.1016/j.tmaid.2020.101613

[2] Brasil. Ministério da Saúde - Painel Coronavírus - Atualizado em: 31/08/2020 - 18:00. Available online: https://covid.saude.gov.br/ (accessed on 31 Aug 2020).

[3] World Health Organization. Novel Coronavirus (2019-nCoV): situation report, 12. World Health Organization. Available online: https://apps.who.int/iris/handle/10665/330777 (accessed on 31 Aug 2020).

[4] Wee, S.K.; Sivalingam, S.P.; Yap, E.P.H. Rapid direct nucleic acid amplification test without RNA extraction for SARS-CoV-2 using a portable PCR thermocycler. *Genes* **2020**, *11*(6), 664, DOI: 10.3390/genes11060664

[5] Sheridan, C. Fast, portable tests come online to curb coronavirus pandemic. *Nat Biotechnol* **2020**, *10*; DOI: 10.1038/d41587-020-00010-2

[6] Schrader C.; et al. PCR inhibitors—occurrence, properties and removal. *J Appl Microbiol.* **2012**, *113*(5):1014–26; DOI: 10.1111/j.1365-2672.2012.05384.x

[7] Interprise. Protocolo de sugerido para extração de RNA viral. Available online: https://interprise.com.br/easyextract/#protocolo-sugerido-para-extracao-de-rna-viral (accessed on 31 Aug 2020).

[8] Smith, E. et al. Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection. *Journal of Clinical Microbiology* **2020**, *58* (9) e01134-20; DOI: 10.1128/JCM.01134-20

[9] Instituto de Biologia Molecular do Paraná. Instruções de Uso Kit Biomol OneStep/COVID-19 Kit. Available online: http://www.ibmp.org.br/pt-br/wp-content/uploads/2020/05/Instru%C3%A7%C3%A3o-de-Uso-Kit-BIOMOL-OneStep_COVID-19-rev-02.pdf (accessed on 31 Aug 2020).

[10] Kim, M.N. et al. Analytical and clinical validation of six commercial Middle East Respiratory Syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR. *Annals of laboratory medicine* **2016**, *36* (5), 450-456; DOI; 10.3343/alm.2016.36.5.450

280 [11] Wilson, I.G. (1997) Inhibition and facilitation of nucleic acid amplification. *Appl Environ Microbiol*
281 **2020**, *63*, 3741–3751; DOI:10.1128/AEM.63.10.3741-3751.1997
282
283 [12] Valentine-Thon, Elizabeth. Quality control in nucleic acid testing—where do we stand? *Journal of*
284 *clinical virology* **2002**, *25*, 13-21; DOI: 10.1016/S1386-6532(02)00196-8
285
286 [13] Dreier, J.; Stormer, M.; Kleesiek, K. Use of bacteriophage MS2 as an internal control in viral reverse
287 transcription-PCR assays. *J Clin Microbiol* **2005**, 43, 4551–4557; 10.1128/JCM.43.9.4551-4557.2005
288
289 [14] Das A.; et al. Removal of real-time reverse transcription polymerase chain reaction (RT-PCR)
290 inhibitors associated with cloacal swab samples and tissues for improved diagnosis of Avian influenza
291 virus by RT-PCR. *J Vet Diagn Invest* **2009**, *21*, 771–778; DOI: 10.1177/104063870902100603
292
293 [15] Kern, M,; et al. Inhibition of Legionella pneumophila PCR in respiratory samples: a quantitative
294 approach. *J Microbiol Methods* **2009**, *79*, 189–193; DOI: 10.1016/j.mimet.2009.08.020
295
296 [16] Monteiro, L.; et al. Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model.
297 *J Clin Microbiol* **1997**, *35*, 995–998.
298
299 [17] Al-Soud, W.A.; Jonsson, L.J.; Radstrom, P. Identification and characterization of immunoglobulin
300 G in blood as a major inhibitor of diagnostic PCR. *J Clin Microbiol* **2000**, 38, 345–350.
301
302 [18] Oikarinen, S. et al. PCR inhibition in stool samples in relation to age of infants. *J Clin Virol* **2009**,
303 *44*, 211–214; DOI: 10.1016/j.jcv.2008.12.017
304
305 [19] Burd, E.M. Validation of laboratory-developed molecular assays for infectious diseases. Clin
306 Microbiol Rev **2010**, *23*, 550–576; DOI: 10.1128/CMR.00074-09
307
308 [20] Anwar, A. et al. Evaluation of preanalytical variables in the quantification of dengue virus by real-
309 time polymerase chain reaction. *J Mol Diagn* **2009**, *11*, 537–542; DOI: 10.2353/jmoldx.2009.080164
310
311 [21] Williams, T.C. et al. Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-
312 CoV-2 in hospitalised patients: a retrospective cohort study. *medRxiv* **2020**; DOI:
313 10.1101/2020.06.19.20135756
314